Oncotelic is an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious disease. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-beta RNA therapeutics that exhibited single agent activity in relapsed/refractory cancer patients in clinical trial setting.
